What are the medical insurance reimbursement conditions for Lynparza/Olaparib? Which patients are eligible for medical insurance?

Olaparib As a targeted anti-cancer drug, its domestic medical insurance coverage has covered multiple key indications, which is of great significance to the cancer treatment population with a heavy financial burden. According to the latest medical insurance catalog policy, Lynparza's reimbursement indications are mainly concentrated in four categories of people, all of which are closely related to BRCA gene mutations or homologous recombination repair defects (HRD). These molecular biomarkers have become the core basis for judging whether patients can enjoy medical insurance support.

1. Olaparib is included in the medical insurance for the treatment of untreated adult patients with advanced epithelial ovarian cancer , fallopian tube cancer or primary peritoneal cancer carrying germline or somatic BRCA mutations (gBRCAm or sBRCAm). After these patients achieve complete remission or partial remission after receiving first-line platinum-containing chemotherapy, they can enter the maintenance treatment phase with olaparib, thereby significantly extending progression-free survival (PFS) and improving the overall treatment benefit. This maintenance treatment model has been widely recognized by many international guidelines, such as the NCCN and ESMO guidelines, which have made it a priority recommendation.

2. Medical insurance also coversHRD-positive patients with advanced ovarian cancer, fallopian tube cancer, or peritoneal cancer who achieve remission after first-line platinum-containing chemotherapy combined with bevacizumab treatment as maintenance treatment scenarios. Determination of HRD status usually requires specialized companion diagnostic testing, such as testing platforms such as FoundationOne or myChoice HRD. This treatment strategy is highly dependent on accurate classification, strengthening the concept of "targeted therapy requires targets."

3. The third category of indications covered by medical insurance is patients with platinum-sensitive recurrent ovarian cancer. When the platinum-containing regimen is reintroduced after disease recurrence and achieves efficacy, olaparib as maintenance treatment can effectively delay recurrence and improve quality of life. This usage has been verified in key studies such as SOLO-2 and Study19, showing that it has a significant prolonging effect on PFS.

4. Olaparib is also included in the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who carry germline or somatic BRCA mutations and have previously failed treatment including a newer endocrine drug (such as abiraterone or enzalutamide). This marks that Lynparza has also been recognized by medical insurance in the field of male tumor treatment, and is an important manifestation of the expansion of precision therapy to a wider range of people.

Reference materials:https://www.lynparza.com/